ReviewClinical and experimental gastroenterology2023
Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management.
Review in Clinical and experimental gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2026Pooled it
- Emerging treatments and current strategies for mineral, vascular, and bone disorders in chronic kidney disease.World journal of nephrology · 2026Review
- Pharmacological management of childhood constipation: Bridging today's gaps with tomorrow's therapies.World journal of clinical pediatrics · 2026Review
- Parkinson Disease and the Gut: A Primer for Gastroenterologists.The American journal of gastroenterology · 2025Review
- Review
- Efficacy and Safety of Tenapanor in IBS-C: A Systematic Review and Meta-Analysis.Gastroenterology & hepatology · 2025Article
- Efficacy of Tenapanor in Patients With IBS-C: A Post Hoc Analysis of Patients With and Without Prior Use of Other IBS-C Prescription Medications From the Phase 3 T3MPO 1 and T3MPO-2 Studies.Gastroenterology & hepatology · 2024Article
- Raising the Bar in the Management of IBS-C.Gastroenterology & hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction (DGBI). IBS significantly impacts the quality of life of patients. Since its pathogenesis is unclear and can be multifactorial, it highlights the need for new and improved pharmaceutical drugs that not only improve bowel symptoms, but also address global IBS symptoms, such as abdominal pain. Tenapanor, a recently Food & Drug Administration (FDA)-approved medication for IBS with constipation (IBS-C), is a small molecule inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.